ValuEngine Lowers Advaxis (NASDAQ:ADXS) to Hold

ValuEngine downgraded shares of Advaxis (NASDAQ:ADXS) from a buy rating to a hold rating in a research note released on Thursday morning, ValuEngine reports.

A number of other research analysts also recently issued reports on ADXS. HC Wainwright reiterated a neutral rating on shares of Aerpio Pharmaceuticals in a report on Wednesday, June 12th. Zacks Investment Research raised Flagstar Bancorp from a hold rating to a buy rating and set a $38.00 price objective for the company in a research report on Monday, July 8th.

Shares of NASDAQ:ADXS opened at $1.27 on Thursday. Advaxis has a 12-month low of $1.21 and a 12-month high of $24.60. The firm has a fifty day moving average of $2.15.

Advaxis (NASDAQ:ADXS) last announced its quarterly earnings results on Monday, June 10th. The biotechnology company reported ($1.32) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.19) by ($0.13). Advaxis had a negative net margin of 126.12% and a negative return on equity of 86.88%. The company had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $0.34 million. As a group, sell-side analysts anticipate that Advaxis will post -2.7 earnings per share for the current fiscal year.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Advaxis by 3.1% in the 4th quarter. BlackRock Inc. now owns 1,446,288 shares of the biotechnology company’s stock worth $275,000 after purchasing an additional 43,368 shares in the last quarter. Deutsche Bank AG boosted its position in shares of Advaxis by 5,970.3% in the 4th quarter. Deutsche Bank AG now owns 562,294 shares of the biotechnology company’s stock worth $106,000 after purchasing an additional 553,031 shares in the last quarter. Finally, Two Sigma Investments LP boosted its position in shares of Advaxis by 2,468.2% in the 4th quarter. Two Sigma Investments LP now owns 369,815 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 355,415 shares in the last quarter. 24.40% of the stock is owned by hedge funds and other institutional investors.

About Advaxis

Advaxis, Inc, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of Listeria monocytogenes (Lm) technology based antigen delivery product in the United States. It is developing therapies for HPV-related cancers using axalimogene filolisbac (AXAL) for the treatment of head and neck cancer.

Featured Story: Forex

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Advaxis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit